Vaccine Info

PRIORIX (MMR-RIT in Clinical Trial)

PRIORIX is a lyophilized mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived from Jeryl Lynn strain) and Wistar RA 27/3 rubella strains of viruses, separately obtained by propagation either in chick embryo tissue cultures (mumps and measles) or MRC5 human diploid cells (rubella).

PRIORIX protects your child against measles, mumps, and rubella. It works by helping the body to make its own antibodies which protect your child against these diseases. As with all vaccines, PRIORIX may not completely protect all people who are vaccinated.

The PRIORIX (MMR-RIT) vaccine is currently licensed outside the USA in over 100 countries, and it is recommended for use in individuals aged ≥9 months according to a 1- or 2-dose schedule depending on the country.

Updated
April 8th, 2019